Essais liés9clinical trials
VilleMálagalocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05152147

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Zanidatamab Parkinson Phase 3 NCT05152147 HERIZON-GEA-01 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers ACTIVE_NOT_RECRUITING
Clemizole HCl Épilepsie Phase 3 NCT05066217 An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome RECRUITING
Empasiprubart IV Myasthénie Phase 2 NCT07673627 ADAPT Forward2 — ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis RECRUITING
Efgartigimod IV Myasthénie À vérifier NCT07294170 ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis RECRUITING
LP352 Épilepsie Phase 3 NCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) ACTIVE_NOT_RECRUITING
LP352 Épilepsie Phase 3 NCT06719141 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) ACTIVE_NOT_RECRUITING
LP352 Épilepsie Phase 3 NCT06908226 A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) ENROLLING_BY_INVITATION
BHV-7000 Épilepsie Phase 2/3 NCT06309966 RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy ACTIVE_NOT_RECRUITING
Efgartigimod IV Myasthénie Phase 2 NCT07284420 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod RECRUITING